Mini-PBPK-Based Population Model and Covariate Analysis to Assess the Complex Pharmacokinetics and Pharmacodynamics of RO7449135, an Anti-KLK5/KLK7 Bispecific Antibody in Cynomolgus Monkeys.

Autor: Cai H; Preclinical and Translational Pharmacokinetics and Pharmacodynamics, Genentech Inc., 1 DNA Way, South San Francisco, California, 94080, USA., Tao X; Preclinical and Translational Pharmacokinetics and Pharmacodynamics, Genentech Inc., 1 DNA Way, South San Francisco, California, 94080, USA., Shim J; BioAnalytical Sciences, Genentech Inc., 1 DNA Way, South San Francisco, California, 94080, USA., Bauer RN; OMNI Biomarker Development, Genentech Inc., 1 DNA Way, South San Francisco, California, 94080, USA., Bremer M; OMNI Biomarker Development, Genentech Inc., 1 DNA Way, South San Francisco, California, 94080, USA., Bu W; BioAnalytical Sciences, Genentech Inc., 1 DNA Way, South San Francisco, California, 94080, USA., LaMar J; BioAnalytical Sciences, Genentech Inc., 1 DNA Way, South San Francisco, California, 94080, USA., Basile R; BioAnalytical Sciences, Genentech Inc., 1 DNA Way, South San Francisco, California, 94080, USA., Dere E; Safety Assessment, Genentech Inc., 1 DNA Way, South San Francisco, California, 94080, USA., Nguyen T; Safety Assessment, Genentech Inc., 1 DNA Way, South San Francisco, California, 94080, USA., Laing S; Safety Assessment, Genentech Inc., 1 DNA Way, South San Francisco, California, 94080, USA., Chan P; Biochemical and Cellular Pharmacology, Genentech Inc., 1 DNA Way, South San Francisco, California, 94080, USA., Yi T; Discovery Immunology, Genentech Inc., 1 DNA Way, South San Francisco, California, 94080, USA., Koerber JT; Antibody Engineering, Genentech Inc., 1 DNA Way, South San Francisco, California, 94080, USA., Sperinde G; BioAnalytical Sciences, Genentech Inc., 1 DNA Way, South San Francisco, California, 94080, USA., Stefanich E; Preclinical and Translational Pharmacokinetics and Pharmacodynamics, Genentech Inc., 1 DNA Way, South San Francisco, California, 94080, USA. stefanich.eric@gene.com.
Jazyk: angličtina
Zdroj: The AAPS journal [AAPS J] 2023 Jun 23; Vol. 25 (4), pp. 64. Date of Electronic Publication: 2023 Jun 23.
DOI: 10.1208/s12248-023-00829-y
Abstrakt: RO7449135, an anti-kallikrein (KLK)5/KLK7 bispecific antibody, is in development as a potential therapy against Netherton's syndrome (NS). In cynomolgus monkey studies, RO7449135 bound to KLK5 and KLK7, causing considerable accumulation of total KLKs, but with non-dose-proportional increase. To understand the complex PKPD, a population model with covariate analysis was developed accounting for target binding in skin and migration of bound targets from skin to blood. The covariate analysis suggested the animal batch as the categorical covariate impacting the different KLK5 synthesis rates between the repeat-dose study and single-dose study, and the dose as continuous covariate impacting the internalization rate of the binary and ternary complexes containing KLK7. To comprehend the mechanism underlying, we hypothesized that inhibition of KLK5 by RO7449135 prevented its cleavage of the pro-enzyme of KLK7 (pro-KLK7) and altered the proportion between pro-KLK7 and KLK7. Besides the pro-KLK7, RO7449135 can interact with other proteins like LEKTI through KLK7 connection in a dose-dependent manner. The different high-order complexes formed by RO7449135 interacting with pro-KLK7 or LEKTI-like proteins can be subject to faster internalization rate. Accounting for the dose and animal batch as covariates, the model-predicted free target suppression is well aligned with the visual target engagement check. The population PKPD model with covariate analysis provides the scientific input for the complex PKPD analysis, successfully predicts the target suppression in cynomolgus monkeys, and thereby can be used for the human dose projection of RO7449135.
(© 2023. The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists.)
Databáze: MEDLINE
Externí odkaz: